UCARTFAP / Cellectis - LARVOL DELTA

Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities (GlobeNewswire) - "Cellectis outlines four new UCART preclinical programs, targeting solid tumors: (i) UCARTMUC1 for Mucin 1-expressing epithelial cancers: Preclinical data indicates that UCARTMUC1 shows strong intratumoral expansion translating into promising preclinical anti-tumor activity in vivo; (ii) UCARTFAPtargeting Cancer Associated Fibroblasts (CAFs) in the tumor microenvironment: TCR knocked out to prevent GVHD and beta-2 microglobulin knocked out to provide resistance to the patient’s own T-cells."

Preclinical • Hematological Malignancies • Oncology